Advertisement

The Clinical Presentation of CLL

  • Daniel CatovskyEmail author
  • Monica Else
  • David Oscier
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

This chapter deals with the basic demographics and the presenting features of CLL and how to assess patients once a diagnosis has been made. CLL is predominantly a disease of the elderly with a preponderance of male patients. New evidence suggests that there are variations in gender incidence according to the clinical status of patients, with a higher male:female ratio in the groups with worse prognosis.

Full blood counts and a physical examination are the basis of the existing staging systems of Rai and Binet. Establishing the patient’s clinical stage sets the scene for the frequency of follow-up, the possible need for therapy and the need for cytogenetic and molecular investigations. Examination of blood films is still important, to identify the presence of prolymphocytes and to consider alternative diagnostic possibilities. In addition, biochemical tests such as beta-2 microglobulin and lactate dehydrogenase are a valuable part of the prognostic evaluation.

Patients may need support to deal with the psychological and quality of life issues arising from their disease.

Keywords

CLL Incidence Clinical presentation Second malignancies Age at diagnosis Gender Rai stage Binet stage 

References

  1. 1.
    Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al., editors. SEER cancer statistics review, 1975–2013. Bethesda: National Cancer Institute; 2016. https://seer.cancer.gov/statfacts/html/clyl.html.
  2. 2.
    Lifetime risk estimates calculated by the Statistical Information Team at Cancer Research UK. Based on data provided by the Office of National Statistics, ISD Scotland, the Welsh Cancer Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry, on request. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll/incidence.
  3. 3.
    Yang SM, Li JY, Gale RP, Huang XJ. The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? Blood Rev. 2015;29:205–13.CrossRefGoogle Scholar
  4. 4.
    Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, et al. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol. 2009;146:418–23.CrossRefGoogle Scholar
  5. 5.
    Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126:2265–73.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun. 2017;8:14175.CrossRefGoogle Scholar
  7. 7.
    International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–90.CrossRefGoogle Scholar
  8. 8.
    Da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population-based cohort. Blood. 2016;128:2181–3.CrossRefGoogle Scholar
  9. 9.
    Catovsky D, Wade R, Else M. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Haematologica. 2014;99:1088–94.CrossRefGoogle Scholar
  10. 10.
    Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, et al. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017;31(10):2251–3.  https://doi.org/10.1038/leu.2017.221.CrossRefPubMedGoogle Scholar
  11. 11.
    Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114:2044–50.CrossRefGoogle Scholar
  12. 12.
    Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Österborg A, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28(2):218–27.  https://doi.org/10.1093/annonc/mdw547.CrossRefPubMedGoogle Scholar
  13. 13.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–34.PubMedGoogle Scholar
  14. 14.
    Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.CrossRefGoogle Scholar
  15. 15.
    Ratterman M, Kruczek K, Sulo S, Shanafelt TD, Kay NE, Nabhan C. Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. Leuk Res. 2014;38:299–303.CrossRefGoogle Scholar
  16. 16.
    Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica. 2016;101:458–65.CrossRefGoogle Scholar
  17. 17.
    Cramer P, Bahlo J, Eichhorst B, Fischer K, Hallek M. Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. Leuk Res. 2014;38:284–5.CrossRefGoogle Scholar
  18. 18.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.CrossRefGoogle Scholar
  19. 19.
    Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017;4:e67–74.CrossRefGoogle Scholar
  20. 20.
    Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood. 2001;98:1979–81.CrossRefGoogle Scholar
  21. 21.
    Tsimberidou AM, Wen S, McLaughlin P, O’Brien S, Wierda WG, Lerner S, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27:904–10.CrossRefGoogle Scholar
  22. 22.
    Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, et al. Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL. Leukemia. 2016;30:2019–25.CrossRefGoogle Scholar
  23. 23.
    Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013;31:930–7.CrossRefGoogle Scholar
  24. 24.
    Kleinstern G, Rishi A, Achenbach SJ, Chaffee KR, Kay NE, Shanafelt TD, et al. Skin cancers among chronic lymphocytic leukemia (CLL) patients - the effect of UV radiation and CLL clinical characteristics. Blood. 2016;128:4772.Google Scholar
  25. 25.
    Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol. 2016;174:767–75.CrossRefGoogle Scholar
  26. 26.
    Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, et al. LDH levels predict progression-free survival in treatment-NaÏVe patients with trisomy 12 chronic lymphocytic leukemia. Blood. 2016;128:3211. Abstract.Google Scholar
  27. 27.
    Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95:1526–33.CrossRefGoogle Scholar
  28. 28.
    Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820–6.CrossRefGoogle Scholar
  29. 29.
    Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30:346–50.CrossRefGoogle Scholar
  30. 30.
    Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Giné E, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1576–80.CrossRefGoogle Scholar
  31. 31.
    Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic lymphocytic leukemia: recent progress and future directions. New York: Alan R. Liss; 1987. p. 253–64.Google Scholar
  32. 32.
    Binet J-L, Catovsky D, Chandra P, Dighiero G, Montserrat E, Rai KR, et al. Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Br J Haematol. 1981;48:365–7.CrossRefGoogle Scholar
  33. 33.
    International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989;110:236–8.CrossRefGoogle Scholar
  34. 34.
    French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol. 1990;76:45–57.CrossRefGoogle Scholar
  35. 35.
    Binet J-L, Catovsky D, Chastang C, Dighiero G, Fooks J, Galton DAG, et al. Workshop: prognostic features of early CLL. Lancet. 1989;334:968–9.CrossRefGoogle Scholar
  36. 36.
    Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–9.CrossRefGoogle Scholar
  37. 37.
    Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141:615–21.CrossRefGoogle Scholar
  38. 38.
    Else M, Cocks K, Crofts S, Wade R, Richards SM, Catovsky D, et al. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma. 2012;53:1289–98.CrossRefGoogle Scholar
  39. 39.
    Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139:255–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Molecular PathologyThe Institute of Cancer ResearchLondonUK
  2. 2.Department of Molecular PathologyRoyal Bournemouth HospitalBournemouthUK

Personalised recommendations